Filtered By:
Condition: SARS
Countries: India Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
Why the U.S. Doesn ’t Have a Nasal Vaccine for COVID-19
The U.S. led the world in quickly developing COVID-19 vaccines—one of the few bright spots in the country’s otherwise criticized response. But while injectable vaccines are effective in protecting people from getting sick with COVID-19, they are less able to block infection. In order to put the pandemic behind us, the world will need a way to stop infections and spread of the virus. That’s where a different type of vaccine, one that works at the places where the virus gets into the body, will likely prove useful.
Here, though, the U.S. is losing its edge. In September, India approved a nasal COVID-19 vacc...
Source: TIME: Health - October 31, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
COVID-19 Reinfections May Be Common —But They’re Not Harmless
By now, you may know—or be—someone who has had COVID-19 two, three, or even four times. Omicron and its subvariants, which are highly contagious and contain mutations that may allow them to evade the body’s vaccine- and infection-acquired immune defenses, have made reinfections an unfortunate but common part of life.
Experts warn that BA.5, which currently accounts for the majority of cases in the U.S., may be particularly likely to cause reinfections, even among people who have had the virus relatively recently. Scientists have similar concerns about BA.2.75, another transmissible Omicron subvariant that...
Source: TIME: Health - July 13, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
COVID-19 Reinfections May Be Common —But They ’ re Not Harmless
By now, you may know—or be—someone who has had COVID-19 two, three, or even four times. Omicron and its subvariants, which are highly contagious and contain mutations that may allow them to evade the body’s vaccine- and infection-acquired immune defenses, have made reinfections an unfortunate but common part of life.
Experts warn that BA.5, which currently accounts for the majority of cases in the U.S., may be particularly likely to cause reinfections, even among people who have had the virus relatively recently. Scientists have similar concerns about BA.2.75, another transmissible Omicron subvariant that...
Source: TIME: Health - July 13, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
Lancet Respir Med. 2022 May 23:S2213-2600(22)00088-1. doi: 10.1016/S2213-2600(22)00088-1. Online ahead of print.ABSTRACTBACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites)...
Source: Respiratory Care - May 26, 2022 Category: Respiratory Medicine Authors: Cameron R Wolfe Kay M Tomashek Thomas F Patterson Carlos A Gomez Vincent C Marconi Mamta K Jain Otto O Yang Catharine I Paules Guillermo M Ruiz Palacios Robert Grossberg Michelle S Harkins Richard A Mularski Nathaniel Erdmann Uriel Sandkovsky Eyad Almasri Source Type: research
Nasal Vaccines Could Help Stop COVID-19 From Spreading —If Scientists Can Get Them Right
When SARS-CoV-2, the virus that causes COVID-19, infiltrates the body, it typically enters through the nose or mouth, then takes root and begins replicating.
But what if it could never get a foothold in the upper airways? That’s the promise of nasal COVID-19 vaccines, which are meant to prevent infection by blocking the virus at its point of entry.
There is not yet a nasal COVID-19 vaccine available in the U.S.—and it’s not clear if or when there will be—but multiple research teams in the U.S., including the National Institute of Allergy and Infectious Diseases, and abroad are working on them. Russi...
Source: TIME: Health - February 15, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
How the Delta Variant Affects Whether You Should Wear a Mask or Not
As infections involving the new Delta variant of the COVID-19 virus continue to increase around the world, including in the U.S., health experts are yet again revisiting advice about who should wear masks and when.
On June 28, the Los Angeles County public health department advised all people, including those who are vaccinated, to wear masks in most indoor public settings, based on the fact that nearly half of the virus from cases in the county that were genetically sequenced now belong to the Delta variant. The variant, first identified in India, is far more contagious than previous strains of SARS-CoV-2, and could cause...
Source: TIME: Health - July 1, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
The So-Called Delta Plus Variant of COVID-19 Is Dangerous But Appears Unlikely to Be a Game-Changer
As if the already worrisome Delta variant, first identified in India, wasn’t concerning enough, now there’s Delta Plus. The latest variant of SARS-CoV-2 was announced by Indian health officials in late June, and labelled by the Indian government as a variant of concern.
By June 24, only about 40 cases of Delta Plus infections were reported by Indian health officials, based on genetic sequencing of the virus from positive patients. But given the original Delta strain’s ability to transmit more efficiently from person to person, and to potentially cause more severe disease, health authorities are rightly ra...
Source: TIME: Health - June 25, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
The Delta Variant Could Soon Become the Dominant COVID-19 Strain. Here ’s What You Need to Know
The COVID-19 pandemic is increasingly becoming an arms race among the emerging variants of the virus, and at the moment, there’s no question which one is winning: the Delta variant—formally known as B.1.617.2—one of four strains to have emerged originally in India. It was just last month that the World Health Organization labeled Delta a “variant of concern”—joining with the Alpha strain, which emerged in the U.K.; the Beta strain, from South Africa; and the Gamma strain, first seen in Brazil. But Delta is fast becoming the most worrisome of the bunch.
Health officials are sounding the a...
Source: TIME: Science - June 15, 2021 Category: Science Authors: Alejandro de la Garza and Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news
Anthony Fauci, 100 Days Into the Biden Administration, Is Finally Getting to Do His Job
When Dr. Anthony Fauci arrived at 1600 Pennsylvania Ave. for his first White House press briefing under the new Biden Administration, he could see things would be different.
It was the day after the Inauguration, and President Joe Biden was eager to get the country’s COVID-19 response back on track. Five minutes before he addressed the public, Fauci spoke with the new President. “He said, ‘I want you to just go and tell the science, explain to people that if we make mistakes, we’re going to fix the mistakes and we’re not going to dwell on the mistakes. Let science be communicated to the public...
Source: TIME: Health - May 18, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an *
In the Dragonfly:
*NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open
The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news
